Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe serious side effects of Mounjaro (tirzepatide) are uncommon but real, and knowing the warning signs matters. Most people on treatment experience mild, short-lived nausea or digestive discomfort — but a small number encounter something more urgent. Mounjaro is a prescription-only medicine; a clinician assesses your full medical history before any prescription is issued, specifically to weigh these risks against your individual circumstances. This page covers what the serious side effects are, how to recognise them, and what to do if they arise.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
There's a common assumption that all the side effects of tirzepatide are gastric, a few days of queasiness and then fine. That picture is mostly accurate for the majority of people, but it misses the smaller category of reactions that need prompt clinical attention rather than patience.
Clinicians distinguish between common and expected effects (nausea, constipation, loose stools, burping, indigestion, fatigue, headache) and serious effects, those that are rarer, potentially harmful, and require action. The NHS patient information for tirzepatide outlines both categories; the more detailed breakdown, including frequencies, is in the Mounjaro SmPC on the eMC.
Seriousness isn't just about intensity. A side effect qualifies as serious when it carries a risk of significant harm, requires hospitalisation, or could worsen rapidly without treatment. For tirzepatide specifically, the major ones are: acute pancreatitis, gallbladder disease, severe allergic reactions, kidney injury secondary to dehydration, and (in people with a history of diabetic eye disease) worsening retinopathy. Understanding the broader picture of Mounjaro's side effects helps to put the serious ones in context, and if you want a focused overview, our page covering the five most commonly reported Mounjaro side effects is a useful starting point.
None of this should be read as a reason to avoid treatment if you're clinically suitable. It is a reason to know what you're watching for.
Pancreatitis is the one clinicians think about most carefully. In January 2026, the MHRA issued a Drug Safety Update highlighting acute pancreatitis as a known but infrequent risk across GLP-1 medicines. The symptom to act on immediately is severe, persistent stomach pain, particularly pain that radiates through to the back, with or without vomiting. This is not ordinary nausea. It tends to be constant rather than cramping, and it does not settle with rest. If that description fits, seek urgent medical help. Do not treat it as a standard digestive side effect.
Gallbladder problems (including gallstones and inflammation of the gallbladder (cholecystitis)) are also listed in the Mounjaro safety data. Watch for sharp pain in the upper right abdomen, particularly after eating, or pain radiating to the right shoulder. Fever and yellowing of the skin or eyes alongside abdominal pain are additional signals.
Serious allergic reactions are rare but possible. Signs include swelling of the face, lips, tongue or throat, difficulty breathing, or a widespread rash developing quickly after injection. This is a 999 situation. A milder localised reaction at the injection site (redness, itching) is much more common and far less concerning, but if swelling spreads or breathing is affected, do not wait.
Kidney problems can develop as a consequence of severe fluid loss from prolonged vomiting or diarrhoea. If you become unable to keep fluids down for more than a day, or notice significantly reduced urination, get medical advice. It is also worth knowing that some people experience particular side effects depending on how their body responds to Mounjaro, which can help you judge whether what you're feeling is typical or warrants closer attention. You can read about managing nausea alongside Mounjaro for practical steps that may reduce the risk of reaching that point.
Yes, and this is one reason the prescribing assessment asks about your medical history in some detail.
People with a personal or family history of medullary thyroid carcinoma (a specific type of thyroid cancer) or a condition called Multiple Endocrine Neoplasia type 2 (MEN2) should not take tirzepatide. This restriction comes from animal studies showing thyroid tumours at high doses; while the human relevance of this finding is not established with certainty, the contraindication is included in the licence and the SmPC.
Pancreatitis history is also a factor. If you've had pancreatitis before, the prescriber will weigh that carefully, it is not an automatic bar in all cases, but it is a conversation that must happen.
For people with diabetic retinopathy, rapid improvement in blood sugar control can, paradoxically, temporarily worsen eye disease. This is relevant mainly in people using tirzepatide to manage type 2 diabetes, but it is worth mentioning to your prescriber if you have a history of diabetic eye disease.
If you are pregnant, breastfeeding, or actively trying to conceive, tirzepatide is not recommended. Women of childbearing age using oral contraceptives should add a non-oral method for the first four weeks of treatment and for four weeks after any dose increase, as tirzepatide can affect pill absorption. Some people also find reassurance in reading about what it looks like when Mounjaro causes no side effects, as individual responses genuinely vary. Hormonal and cycle-related effects are a separate but connected topic worth reviewing. Our clinical team (including our lead prescriber) goes through all of this at consultation.
Any suspected serious side effect from a medicine can be reported to the MHRA via the Yellow Card scheme. This applies to anyone (patient, carer, or clinician) and the information genuinely feeds into national safety monitoring. You don't need to be certain it's caused by the medicine to report it. Suspected links count.
If you're being treated through a regulated pharmacy such as ours, your prescriber is your first point of clinical contact for questions about reactions. nume provides priority aftercare seven days a week, if something doesn't feel right, getting in touch directly is always the right call. We'd rather hear from you than have you second-guessing a symptom alone.
For broader questions about whether tirzepatide is appropriate for your situation (or if you've read this page and want to understand how your specific history would be assessed) a free consultation with our prescribers is the place to start. They discuss suitability, including side effects, as a standard part of every review. You can also explore the service FAQs or contact the team directly with a question before you start.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.